There Are Only 3 Ways To Increase Your IGF-1 (How To Pick The Right One)

Your pituitary gland is not the whole story when it comes to growth hormone, and understanding why changes how you think about every compound in this space.

Here is the full chain before anything else. Your hypothalamus releases something called GHRH, which is growth hormone releasing hormone, and that signal travels to your pituitary gland and tells it to release growth hormone into the blood. That growth hormone then travels to your liver, where the liver converts it into something called IGF-1, which is insulin-like growth factor 1, the molecule that actually drives most of the tissue-building and fat-burning effects people associate with growth hormone. The whole system runs on a feedback loop, meaning when IGF-1 climbs high enough, your brain responds by releasing somatostatin, which is a brake signal that tells the pituitary to slow down. That loop is the entire reason why three different categories of compounds produce three completely different outcomes.

The first category is GHRH analogs, which include Sermorelin, CJC-1295, and Tesamorelin. These peptides mimic the hypothalamic signal, so when you inject one, you are telling your pituitary to release more of your own growth hormone. The pituitary responds, your liver makes more IGF-1, and the feedback loop runs exactly as designed. That is not a flaw, it is the feature. Because the loop stays intact, your body will not let IGF-1 climb past the ceiling it has set for you. The somatostatin brake activates, and your output stabilizes within your own physiological range. This is why these compounds carry a lower risk profile, and also why they have a limited ceiling.

Tesamorelin is the most studied compound in this category. In a 2007 randomized controlled trial published in the New England Journal of Medicine, Tesamorelin reduced visceral fat by roughly 15 percent over 26 weeks in HIV patients with lipodystrophy, which is a condition involving abnormal fat accumulation around the organs. That is a meaningful reduction, and it is what earned Tesamorelin its reputation as the visceral fat peptide. But that reputation creates a misunderstanding worth addressing directly.

Growth hormone does not preferentially target visceral fat because of something special about Tesamorelin. It targets visceral fat because visceral adipose tissue has a higher density of growth hormone receptors than subcutaneous fat does, so when GH rises through any mechanism, visceral depots respond first and most strongly. A 1997 clinical trial by Johannsson and colleagues showed the same visceral fat reduction pattern using pharmaceutical HGH in abdominally obese men, with significant reductions in abdominal fat mass alongside improvements in glucose and lipoprotein metabolism. The mechanism is the same regardless of which compound drove the GH elevation. Tesamorelin just happens to be the version with the most rigorous trial data behind it.

The second category is exogenous growth hormone, meaning pharmaceutical HGH injected directly. This skips the pituitary entirely. You are not asking your body to make GH, you are replacing it from outside. Because the signal bypasses the feedback loop rather than entering through it, your IGF-1 can climb past whatever ceiling your hypothalamus and pituitary would have enforced. This is the mechanism behind every long-term IGF-1 elevation protocol, and the tradeoff is that it requires sustained use to maintain elevated levels, which makes cost and monitoring non-negotiable rather than optional.

There is also a suppression effect worth knowing about. When exogenous GH is present, the pituitary detects it and reduces its own output. A study by Rosenthal and colleagues in 1986 demonstrated that exogenous growth hormone directly inhibits GHRH-induced GH secretion in normal men, meaning the pituitary goes quiet when it senses GH coming from outside. A later study by Hashimoto and colleagues in 2000 confirmed this suppressive effect even with the 20 kilodalton isoform of GH. This is exactly why stacking a GHRH analog on top of pharmaceutical HGH is redundant. You are paying for a pituitary signal, and the pituitary is not listening.

The third category is IGF-1 LR3, which is a long-acting analog of IGF-1 itself. This skips the entire upstream system. No hypothalamus signal, no pituitary release, no liver conversion. You are injecting the downstream molecule directly into circulation. The potency is higher because nothing is lost in translation, and the risk profile reflects that. IGF-1 LR3 has a significantly longer half-life than native IGF-1, which is what makes it effective but also what makes receptor desensitization a real concern with prolonged use. The receptors that respond to IGF-1 will downregulate when the signal is constant, which is why cycling is not optional but structural, typically six to eight weeks on before taking a full break to let receptor sensitivity recover.

Chapman and colleagues published data in 1998 showing that elevated free IGF-1 specifically, not bound IGF-1, suppresses GH release from the pituitary, which confirms that the feedback loop responds to the free fraction of the molecule. IGF-1 LR3's modified structure changes how it interacts with binding proteins, keeping more of it in the free, active form, which amplifies both the anabolic effect and the suppression signal back to the hypothalamus and pituitary.

The practical structure falls out of the biology. If your goal is to restore GH output that has declined with age and support sleep quality, recovery, and gradual body composition improvements without pushing past your body's natural ceiling, a GHRH analog is the appropriate tool. If your goal is to maintain IGF-1 above your natural ceiling for extended periods, pharmaceutical HGH is the appropriate tool. If your goal is a concentrated, short-term IGF-1 spike for a specific outcome and you are willing to cycle strictly and monitor, IGF-1 LR3 is the appropriate tool. None of these are interchangeable, and none of them will produce meaningful fat loss results in the absence of a caloric deficit, because GH-mediated lipolysis, which is the process by which growth hormone signals fat cells to release stored fat for fuel, requires an energy deficit to translate into actual fat loss rather than just elevated circulating fatty acids.

The reason people end up stacking compounds or rotating through them without results is usually that they are treating this as a category of things that raise IGF-1, when they are actually three completely different points of entry into the same system, each with its own feedback dynamics, ceiling, and appropriate use case.

The compound is not the decision. Understanding where in the loop you are intervening is.

---

References

1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357(23):2359-70. DOI: 10.1056/NEJMoa072375
2. Stanley TL, Grinspoon SK. (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 25(2):59-65. DOI: 10.1016/j.ghir.2014.12.005
3. Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. DOI: 10.1210/er.2008-0027
4. Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. J Clin Endocrinol Metab 85(2):601-6. DOI: 10.1210/jcem.85.2.6377
5. Rosenthal SM, Hulse JA, Kaplan SL, Grumbach MM. (1986). Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men. J Clin Invest 77(1):176-83. DOI: 10.1172/JCI112273
6. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO. (1998). Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I: evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83(8):2836-42. DOI: 10.1210/jcem.83.8.5040
7. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82(3):727-34. DOI: 10.1210/jcem.82.3.3809

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness